NeoClone specializes in the development of custom monoclonal antibodies, utilizing advanced techniques such as hybridoma technology and phage display. Their services cater to a variety of needs, including the production of llama VHH, human scFv, and traditional mouse hybridomas. The company emphasizes a collaborative approach with clients to ensure that the antibody development process is tailored to the specific requirements of the target antigen. This includes generating a robust immune response and employing various methods such as alternate cell line immortalization and genetic immunization to enhance the efficiency of antibody production.

The NeoAb process is a key component of NeoClone's technology, designed to address the challenges of generating antibodies against difficult targets. This proprietary approach allows for the discovery and development of monoclonal antibodies with specific characteristics, ensuring high-quality results. NeoClone also offers services for antibody purification, utilizing methods like FPLC with Protein A resin to meet the diverse needs of their clients. Overall, NeoClone's commitment to innovation and client collaboration positions them as a valuable partner in the field of antibody development for research and diagnostic applications.

United States

NeoClone produces high-quality monoclonal antibody products for the biotechnology and research markets. In addition to generating monoclonals through the traditional fusion technology NeoClone holds exclusive license to the ABL-MYC retroviral transformation system, a technique that produces monoclonal antibodies -- "NeoClone®"-brand or "NeoAb®" antibodies -- in an accelerated time and with cost savings. This allows NeoClone to provide custom antibodies faster and more cost effective.

NeoClone

Company Details